UBS reiterates Buy rating on Regeneron Pharma (REGN), sees an attractive setup
Tweet Send to a Friend
UBS analyst Colin Bristow reiterated a Buy rating and $914.00 price target on Regeneron Pharma (NASDAQ: REGN)."The highly anticipated BOREAS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
